A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C

摘要: Background & Aims Adherence to antiviral treatment is important achieve sustained virological response (SVR) in chronic hepatitis C (CHC). We evaluated the efficiency of a multidisciplinary support programme (MSP), based on published HIV experience, increase patient adherence and efficacy pegylated interferon alfa-2a ribavirin CHC. Methods 447 patients receiving were distributed into 3 groups: control group (2003–2004, n=147), MSP (2005–2006, n=131), MSP-validation (2007–2009, n=169). The included two hepatologists, nurses, one pharmacist, psychologist, administrative assistant, psychiatrist. Cost-effectiveness analysis was performed using Markov model. Results SVR rates higher (94.6% 77.1%) (91.7% 74.6%) groups compared controls (78.9% 61.9%) ( p vs. (67.7% 48.9%, =0.02) with genotypes 2 or (87.7% 81.4%, =n.s.). main predictive factor genotype 1. rate psychiatric disorders (n=95, 90.5%) (n=28, 75.7%) =0.02). cost per € 13,319 16,184 group. achieved more quality-adjusted life years (QALYs) (16.317 QALYs) than (15.814 dominant all genotypes. Conclusions improves compliance increases CHC, being cost-effective.